Potassium chloride, meets analytical specification of Ph. Eur., BP, USP, FCC, E508, ≤0.0001% Al

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,598 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Glucose homeostasis is tightly regulated to meet the energy requirements of the vital organs and maintain an individual’s health. Glucose metabolism includes glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, oxidative phosphorylation and other metabolic pathways. Glucose is the major carbon source that provides the main energy for life. Glucose metabolism dysregulation is also implicated in many diseases such as diabetes, heart disease, neurodegenerative diseases and even cancer.

MCE offers a unique collection of 1,052 compounds related to glucose metabolism, which target glucose metabolism related targets, such as GLUT, Hexokinase, Pyruvate Kinase, IDH, etc. MCE glucose metabolism library is a powerful tool for studying glucose metabolism and drug discovery of diseases related to glucose metabolism.

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 510 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

The incidence and significance of central nervous system diseases are increasing at an alarming rate all over the world. Although substantial research efforts have been applied to develop new CNS-active drugs, only a few CNS disorders are addressed satisfactorily, while the remaining ones pose significant clinical challenges. Blood-brain barrier (BBB) permeability is one of the most important limiting factors in the design and development of novel CNS-targeted pharmaceuticals for the treatment of neurological disorders.

Carefully selected from the HTS Compound Collection to meet the parameters optimized for high BBB-permeability, our CNS Focused Screening Library comprising over 30,300 structurally-diverse and potentially CNS-active screening compounds. This original Screening Compound Library is aimed at supporting CNS drug design projects and HTS efforts in search for novel neurotherapeutics.

Covalent inhibitors are small molecules that can bind specifically to target proteins through covalent bonds and inhibit their biological functions. Although for a long time, covalent targeting has been playing a subordinate role in drug discovery, with an increasing number of reports on successful clinical applications of such drugs, the potential of these agents is now being acknowledged. Currently, cysteine is the most common covalent amino acid residue in a variety of covalent drugs, and various warheads have been developed that can react with cysteine, providing the key building blocks for covalent drugs to form covalent bonds.

To meet the development needs of covalent inhibitors targeting cysteine, MCE has designed a unique collection of 4,845 compounds with different covalent warheads that target cysteine. The MCE Cysteine Targeted Covalent Library is designed using the following covalent warheads: Acrylamides, Propiolic acid ester, Dimethylamine functionalized acrylamides, Chloroacetamides, Acrylonitrile, 2-Cyanoacrylamide, Aziridine, Haloacetamide, etc.

Covalent inhibitors are small molecules that can bind specifically to target proteins through covalent bonds and inhibit their biological functions. Although for a long time, covalent targeting has been playing a subordinate role in drug discovery, with an increasing number of reports on successful clinical applications of such drugs, the potential of these agents is now being acknowledged. Currently, cysteine is the most common covalent amino acid residue in a variety of covalent drugs, and various warheads have been developed that can react with cysteine, providing the key building blocks for covalent drugs to form covalent bonds.

To meet the development needs of covalent inhibitors targeting cysteine, MCE has designed a unique collection of 3,389 fragments with different covalent warheads that target cysteine. The MCE Cysteine Targeted Covalent Fragment Library is designed using the following covalent warheads: Acrylamides, Propiolic acid ester, Dimethylamine functionalized acrylamides, Chloroacetamides, Acrylonitrile, 2-Cyanoacrylamide, Aziridine, Haloacetamide, etc. All fragments are pre-filtered with the Rule of Three restrictions which can be used for fragment-based covalent drug development.

The most prominent mechanism of action of kinase inhibitors is their competition with ATP by binding to the hinge region of the kinase protein. Once the kinase is blocked by an inhibitor, it loses the ability to transfer phosphate groups from ATP to other molecules, resulting in the loss of kinase activity.

The hinge-binding region of kinase inhibitors mimics the interaction pattern between the ATP nucleobase and the kinase. MCE extracted thousands of kinase inhibitors from the ChEMBL database and isolated their molecular fragments. In certain cases, the amino and amide groups on the molecular fragments are crucial for binding in the hinge region. Therefore, we enhanced the diversity of the collected results by adding these two groups to unoccupied positions on the ring system. Subsequently, the fragments were assessed for their hinge region binding ability via docking at distinct kinases, we also applied pharmacophore constraints to ensure interactions with key amino acids in the kinase hinge region, ultimately obtaining kinase-related molecular fragments.

MCE provides over 10,000 kinase fragment molecules that meet the above requirements and are available off the shelf, serving as an effective tool for screening and developing drugs targeting kinases.

Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical probes of protein function. 3-dimensionality (3D) diversity is pivotal because the molecular shape is one of the most important factors in molecular recognition by a biomolecule. There is a developing appreciation that 3D fragments could offer opportunities that are not provided by 2D fragments.

MCE 3D Diverse Fragment Library consists of 5,400 non-flat fragment-like molecules (average Fsp3 value 0.58). More than 4,700 fragment compounds contain at least one chiral center in the structure. The key concepts that underlie the library design were 3D shape, structural diversity, reactive functionality and fragment-like. This 3D Diverse Fragment Library brings higher fragment hit optimization and increases the likelihood to find innovative hits in FBDD.

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 973 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

MCE The MedChemExpress? 8-Channel Handheld Screw Cap Decapper is a necessary tool for handling thousands of screw cap tubes. It can cap and open various types of screw cap tubes, making it convenient and fast to operate. This improves experimental efficiency and meets different needs.

USP1 Human Pre-designed siRNA Set A contains three designed siRNAs for USP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP10 Human Pre-designed siRNA Set A contains three designed siRNAs for USP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP11 Human Pre-designed siRNA Set A contains three designed siRNAs for USP11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP12 Human Pre-designed siRNA Set A contains three designed siRNAs for USP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP13 Human Pre-designed siRNA Set A contains three designed siRNAs for USP13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP14 Human Pre-designed siRNA Set A contains three designed siRNAs for USP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP15 Human Pre-designed siRNA Set A contains three designed siRNAs for USP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP16 Human Pre-designed siRNA Set A contains three designed siRNAs for USP16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP18 Human Pre-designed siRNA Set A contains three designed siRNAs for USP18 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP19 Human Pre-designed siRNA Set A contains three designed siRNAs for USP19 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP2 Human Pre-designed siRNA Set A contains three designed siRNAs for USP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP20 Human Pre-designed siRNA Set A contains three designed siRNAs for USP20 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP21 Human Pre-designed siRNA Set A contains three designed siRNAs for USP21 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP22 Human Pre-designed siRNA Set A contains three designed siRNAs for USP22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP24 Human Pre-designed siRNA Set A contains three designed siRNAs for USP24 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP25 Human Pre-designed siRNA Set A contains three designed siRNAs for USP25 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP26 Human Pre-designed siRNA Set A contains three designed siRNAs for USP26 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP28 Human Pre-designed siRNA Set A contains three designed siRNAs for USP28 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP29 Human Pre-designed siRNA Set A contains three designed siRNAs for USP29 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP3 Human Pre-designed siRNA Set A contains three designed siRNAs for USP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP30 Human Pre-designed siRNA Set A contains three designed siRNAs for USP30 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP31 Human Pre-designed siRNA Set A contains three designed siRNAs for USP31 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP32 Human Pre-designed siRNA Set A contains three designed siRNAs for USP32 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP33 Human Pre-designed siRNA Set A contains three designed siRNAs for USP33 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP34 Human Pre-designed siRNA Set A contains three designed siRNAs for USP34 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP35 Human Pre-designed siRNA Set A contains three designed siRNAs for USP35 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP36 Human Pre-designed siRNA Set A contains three designed siRNAs for USP36 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP37 Human Pre-designed siRNA Set A contains three designed siRNAs for USP37 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.